Style | Citing Format |
---|---|
MLA | Varshosaz J, et al.. "Efavirenz Oral Delivery Via Lipid Nanocapsules: Formulation, Optimisation, and Ex-Vivo Gut Permeation Study." IET Nanobiotechnology, vol. 12, no. 6, 2018, pp. 795-806. |
APA | Varshosaz J, Taymouri S, Jahaniannajafabadi A, Alizadeh A (2018). Efavirenz Oral Delivery Via Lipid Nanocapsules: Formulation, Optimisation, and Ex-Vivo Gut Permeation Study. IET Nanobiotechnology, 12(6), 795-806. |
Chicago | Varshosaz J, Taymouri S, Jahaniannajafabadi A, Alizadeh A. "Efavirenz Oral Delivery Via Lipid Nanocapsules: Formulation, Optimisation, and Ex-Vivo Gut Permeation Study." IET Nanobiotechnology 12, no. 6 (2018): 795-806. |
Harvard | Varshosaz J et al. (2018) 'Efavirenz Oral Delivery Via Lipid Nanocapsules: Formulation, Optimisation, and Ex-Vivo Gut Permeation Study', IET Nanobiotechnology, 12(6), pp. 795-806. |
Vancouver | Varshosaz J, Taymouri S, Jahaniannajafabadi A, Alizadeh A. Efavirenz Oral Delivery Via Lipid Nanocapsules: Formulation, Optimisation, and Ex-Vivo Gut Permeation Study. IET Nanobiotechnology. 2018;12(6):795-806. |
BibTex | @article{ author = {Varshosaz J and Taymouri S and Jahaniannajafabadi A and Alizadeh A}, title = {Efavirenz Oral Delivery Via Lipid Nanocapsules: Formulation, Optimisation, and Ex-Vivo Gut Permeation Study}, journal = {IET Nanobiotechnology}, volume = {12}, number = {6}, pages = {795-806}, year = {2018} } |
RIS | TY - JOUR AU - Varshosaz J AU - Taymouri S AU - Jahaniannajafabadi A AU - Alizadeh A TI - Efavirenz Oral Delivery Via Lipid Nanocapsules: Formulation, Optimisation, and Ex-Vivo Gut Permeation Study JO - IET Nanobiotechnology VL - 12 IS - 6 SP - 795 EP - 806 PY - 2018 ER - |